ClinicalTrials.gov
public full text
Public Domain
Nicotinic Receptors and Schizophrenia
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are non-smokers. The study drug may also maintain abstinence from cigarette smoking and improve other symptoms in patients with schizophrenia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia#902582
- Study of the Effects of Mecamylamine and Varenicline in Schizophrenia#899678
- Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors#1093608
- Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment#826878
- tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia#992905
Record · ID 1138040
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive